From: Data-driven FDG-PET subtypes of Alzheimer’s disease-related neurodegeneration
CN group | AD group, limbic-predominant (S1) | AD group, typical (S2) | AD group, cortical-predominant (S3) | P value, global comparison (S1, S2 and S3) | Pair-wise comparisons | |||
---|---|---|---|---|---|---|---|---|
S1 vs S2 | S1 vs S3 | S2 vs S3 | ||||||
Demographics | ||||||||
n (%) | 179 | 79 (44.6%) | 86 (48.6%) | 12 (6.8%) | ||||
Age, years | 73.8 (6.5) | 75.4 (6.9) | 73.2 (5.7) | 68.0 (7.7) | 0.007 | 0.149 | 0.015 | 0.088 |
Sex, female (%) | 50% | 49% | 38% | 50% | 0.332 | |||
Education, years | 16.6 (2.5) | 15.4 (3.1) | 15.5 (2.6) | 16.3 (2.6) | 0.544 | |||
Cognition | ||||||||
MMSE | 29.1 (1.2) | 23.4 (1.9) | 23.2 (2.2) | 22.0 (2.2) | 0.037 | 0.798 | 0.165 | 0.200 |
ADNI-MEM | 1.04 (0.62) | − 0.85 (0.55) | − 0.90 (0.49) | − 1.31 (0.44) | 0.012 | 1 | 0.025 | 0.028 |
ADNI-EF | 0.92 (0.83) | − 0.65 (0.86) | − 1.11 (0.89) | − 1.73 (0.81) | < 0.001 | 0.002 | < 0.001 | 0.043 |
ADNI-DIFF | 0.13 (0.72) | − 0.21 (0.69) | 0.21 (0.85) | 0.41 (0.74) | < 0.001 | 0.004 | 0.029 | 0.723 |
ADNI-VS | 0.23 (0.59) | − 0.42 (0.8) | − 0.67 (1.01) | − 1.15 (1.08) | 0.085 | |||
ADNI-Lan | 0.89 (0.71) | − 0.63 (0.95) | − 0.83 (0.88) | − 1.11 (0.78) | 0.03 | 0.406 | 0.406 | 0.588 |
Biomarkers | ||||||||
APOE ε4 (%) | 28% | 81% | 79% | 58% | 0.222 | |||
AV45-PET SUVR | 1.11 (0.18) | 1.43 (0.14) | 1.47 (0.17) | 1.4 (0.17) | 0.145 | |||
CSF Aβ, pg/ml | 1392 (663) | 598 (163) | 585 (225) | 629 (169) | 0.686 | |||
CSF t-tau, pg/ml | 236 (92) | 374 (143) | 374 (154) | 402 (124) | 0.978 | |||
CSF p-tau, pg/ml | 22 (9) | 38 (16) | 37 (16) | 39 (14) | 0.881 | |||
HV | 4.97 (0.38) | 4.05 (0.51) | 4.1 (0.38) | 4.46 (0.46) | 0.09 | |||
CTV | 87.39 (6.28) | 75.84 (6.95) | 73.99 (6.23) | 70.04 (5.88) | 0.006 | 0.136 | 0.026 | 0.136 |
HV:CTV ratio | 57.11 (5.29) | 53.67 (7.57) | 55.74 (6.61) | 64.29 (10.08) | < 0.001 | 0.136 | < 0.001 | < 0.001 |
WMH | 6.1 (10.4) | 8.0 (10.0) | 5.8 (7.9) | 8.1 (12.7) | 0.262 |